
Follow the clinical sequence of testosterone testing, from symptoms and a first result to repeat measurements and targeted follow-up biomarkers.

A structured testosterone evaluation addresses the uncertainty of an initial low result by clarifying whether it is consistent and fits the clinical picture.
This article is for informational purposes only and is not medical advice. A qualified clinician should decide which tests are appropriate and interpret the findings in your individual situation.
Before a blood sample is collected, the timing and circumstances need attention. The European Association of Urology (EAU) recommends morning fasting testosterone testing between 07:00 and 10:00 for the general population. Its guideline explains that testosterone levels are higher in the morning.
Fasting also matters. The EAU cites evidence that non-fasting testing can underestimate total testosterone by more than 30% in some circumstances. That finding is not a correction factor that someone can apply to an individual report.
Sleep schedules require separate consideration. The guideline notes that the usual morning window may not fit night-shift workers because their daily rhythm is more closely tied to sleep patterns. Shift work therefore belongs in the conversation about when a sample should be collected.
The EAU also advises avoiding testosterone measurement during acute illness. It notes that acute illness can be associated with functional hypogonadism. A clinician should consider this context when deciding whether the planned test timing is appropriate.
The practical preparation is to confirm the intended sampling time and fasting requirements with the requesting clinician or laboratory. Mention relevant illness and sleep or shift-work patterns. Understanding how collection conditions affect comparisons helps explain why preparation is part of the evaluation rather than an administrative detail.
The assessment starts with symptoms and medical history rather than a target testosterone number. The EAU bases diagnosis on compatible symptoms or signs together with consistently low testosterone. Both parts of that assessment matter.
The guideline lists reduced libido and erectile dysfunction among the more specific sexual symptoms. Fewer spontaneous or morning erections also fall into that group. Reduced energy and sleep disturbance are less specific symptoms, as are concentration difficulties.
These symptoms are not exclusive to testosterone deficiency. The EAU says they need interpretation within the broader clinical and biochemical context. It also cautions that symptom questionnaires have poor specificity for systematic screening, so a questionnaire score is not a substitute for assessment.
The clinician reviews chronic or systemic conditions alongside medication and substance use. The EAU recommends checking for diseases and substances that may interfere with testosterone production or action. This review helps establish the context in which a laboratory result will be interpreted.
A useful preparation for the appointment is a clear account of relevant symptoms and their timing. Medical conditions and medication or substance use also belong in that account. The purpose is to support the clinical history rather than to assign a hormone explanation to every concern.
The initial measurement is interpreted using the collection conditions already discussed. The EAU specifies a reliable assay, meaning a dependable laboratory measurement method. A numerical result is useful only when the clinician can place it within that testing context.
At this stage, total testosterone provides the laboratory finding that will be reviewed alongside the history. It does not replace the symptom assessment or the review of relevant health conditions.
When total testosterone falls below the EAU's stated threshold, the guideline recommends repeat measurement on separate occasions. Its diagnostic basis includes low morning total testosterone measured on at least two occasions. Confirmation is also required before testosterone therapy is considered.
The repeat measurement addresses a specific question: does the low finding persist rather than appear only once? The review also considers whether the samples were collected under appropriate conditions. A repeat result is not simply another number added to the record.
If the measurements differ, their timing and collection circumstances become important to the comparison. The clinician reviews those differences rather than selecting whichever result seems more convincing. This is why confirmation is a separate clinical step.
If repeat measurements remain low, the next task may be to understand the broader hormone pattern and investigate a possible cause. The EAU supports additional hormone tests according to the clinical picture. These tests are selected for a reason rather than added automatically as a standard panel for every man.
The clinician can explain which question each requested measurement is intended to answer. The distinction matters: confirming a testosterone finding and investigating its cause are related tasks, but they are not identical.
The starting point on the report is the named measurement together with its numerical value and units. Total testosterone is the initial measurement discussed in this evaluation. Additional hormone results may appear if the clinician has requested them.
The EAU identifies total testosterone of 12 nmol/L (3.5 ng/mL) as a threshold it considers reliable for diagnosing late-onset hypogonadism. It also requires the result to be integrated with the patient's symptom profile. This is a guideline threshold within a clinical assessment, not a stand-alone label for the person reading the report.
Results near a threshold need particular attention to testing conditions and laboratory methods. A small numerical difference should not be interpreted separately from those details. The physician's task is to judge the combined evidence rather than turn the threshold into a self-diagnosis rule.
The EAU identifies liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the most accurate method for sex-steroid evaluation. It also reports that standardized automated immunoassays for total testosterone correlate well with LC-MS/MS. The guideline therefore does not support dismissing all routine testosterone assays as inaccurate.
Free testosterone requires a different caution. The EAU says available immunoassays cannot accurately estimate free testosterone and advises against direct estimation with those methods. A clinician reviewing this result needs to understand how it was obtained.
A survey cited by the EAU reported variation in laboratory practices across 27 European countries. The guideline also notes methodological criticisms of that survey. Its practical recommendation is close collaboration between clinicians and laboratories to support accurate and comparable measurement.
For the patient, the useful question is whether the method matters to the interpretation of this particular report. There is no need to choose a preferred result solely because a laboratory method sounds more advanced.
The EAU recommends considering sex hormone-binding globulin (SHBG) measurement and free-testosterone calculation when SHBG is likely to be altered. These results can help a clinician interpret the testosterone finding when the clinical situation calls for them.
Total testosterone and calculated free testosterone should therefore be read as related measurements with different roles. The presence of both on a report does not mean the reader should choose one and disregard the other. Further background on why SHBG matters to the assessment can help prepare questions about that relationship.
The guideline also recommends luteinising hormone (LH) and follicle-stimulating hormone (FSH) testing to help distinguish types of hypogonadism. Their role is to support the investigation of the hormone pattern and possible cause.
Prolactin is another targeted measurement. The EAU recommends it when low sexual desire or other suggestive symptoms accompany secondary hypogonadism. This indication is more specific than simply having a low total testosterone result.
Physicians structure the review around the symptom history and the consistency of the testosterone measurements. They then consider collection conditions and any additional hormone findings. The central question is whether those pieces form a coherent clinical picture.
This makes the report a record to discuss rather than a set of independent verdicts. A useful explanation should make clear which finding prompted confirmation and what any further test is intended to clarify.
Once results are available, arrange a review with the clinician responsible for the evaluation. Bring the reports and a record of the collection circumstances. Include relevant symptoms and their timing alongside your medical and medication history.
Ask whether confirmation is complete and whether any additional testing has a specific purpose. If results differ, ask which contextual details matter to their comparison. The responsible next step is a clinical explanation of the combined findings rather than an independent diagnosis or a decision to start hormone treatment.
Reading an added hormone result as a verdict can obscure why it was measured, so Testostra explains biomarkers within their clinical context. Its evidence-led coverage helps men make sense of total testosterone, free testosterone and SHBG before discussing a report with a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra